PHARMEX AS

Operating

Velkommen til Pharmex

nettbutikk,helse,hud,intimpleie,kvinnehelse,smerte,naturlig,multi-gyn, multi-mam,retisan,nasaleze allergi pollen,naturlig,smertebehandling

Engroshandel med sykepleie- og apotekvarer. Postordre-/Internetthandel med helsekost. Engroshandel med sykepleie og apotekvarer, og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.

Handel og konsulenttjenester med legemidler og beslektede produkter, herunder medisinsk utstyr.

Keywords

pharmaceuticalshospital equipmentorthopedic articles

Organization

CEO: GB
Gisle Bakken1957
Chairman of the board: OB
Ole Bækken1954
Years since formation: 27 years; since Oct 5, 1999
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 1,940; 1 share class
Total number of shareholders: 2; 1 company, 1 person

Financials

Total operating income 2024: 33,246,200; NOK
Annual total result 2024: 5,168,572; NOK
Total equity 2024: 8,065,492; NOK

Last update: Dec 12, 2025

Management

Management / administration

Name	Role	Shares
GB Gisle Bakken 1957	Managing Director/CEO	50 % directly

Board

Name	Role	Shares
OB Ole Bækken 1954	Chairman	50 % indirectly
GB Gisle Bakken 1957	Board Member	50 % directly

Others

Name	Role	Shares
U UNIC REVISJON AS	Auditor	-
S STABEKK REGNSKAPSSERVICE AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
OB Ole Bækken 1954	Chairman	50 % indirectly
GB Gisle Bakken 1957	Managing Director/CEO, Board Member	50 % directly

Last update: Apr 13, 2023

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
B BÆKKEN EIENDOM AS	Ordinary shares	970	50 %
GB Gisle Bakken 1957	Ordinary shares	970	50 %

Last update: Jun 2, 2025

Financials

in NOK

Summary

Year	2024	2023	2022	2021
Total operating income	33,246,200	24,793,196	22,672,894	17,151,111
Annual Total Result	5,168,572	2,818,669	2,603,572	1,821,027
Total assets	15,408,385	10,925,682	9,224,312	9,109,191
Total liabilities	7,342,893	4,028,762	3,146,060	4,134,511
Total equity	8,065,492	6,896,920	6,078,252	4,974,680

P&L

Year	2024	2023	2022	2021
Total operating income	33,246,200	24,793,196	22,672,894	17,151,111
Total operating costs	26,823,569	21,567,302	18,844,650	15,447,902
Operating result	6,422,632	3,225,894	3,828,244	1,703,209
Financial income/costs	208,248	388,379	-490,301	631,441
Profit before tax	6,630,879	3,614,274	3,337,944	2,334,650
Total tax & extraordinary income/cost	1,462,307	795,605	734,372	513,623
Annual Total Result	5,168,572	2,818,669	2,603,572	1,821,027

Balance overview

Year	2024	2023	2022	2021
Total fixed assets	0	0	0	0
Total current assets	15,408,385	10,925,682	9,224,312	9,109,191
Total assets	15,408,385	10,925,682	9,224,312	9,109,191
Short term debt	7,150,504	3,812,308	2,864,207	3,750,916
Long term debt	192,389	216,454	281,853	383,595
Total liabilities	7,342,893	4,028,762	3,146,060	4,134,511
Contributed capital	601,400	601,400	601,400	601,400
Retained earnings	7,464,092	6,295,520	5,476,852	4,373,280
Total equity	8,065,492	6,896,920	6,078,252	4,974,680
Total equity and liabilities	15,408,385	10,925,682	9,224,312	9,109,191

Classification

21st company classification

BETA

Small company

PHARMEX AS981 070 968

PHARMEX AS

Keywords

Links

Organization

Ownership

Financials

Management

Management / administration

Board

Others

Top 10 individual shareholders

Ownership

Company shareholders

Financials

Summary

P&L

Balance overview

Classification